Immunic Therapeutics

Developing Selective Oral Drugs in Immunology

NASDAQ: IMUX | June 23, 2020

BMO 2020 Prescriptions for Success Healthcare Conference

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunic undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management. Risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Immunic's plans to develop and commercialize its product candidates, including IMU-838, IMU-935 and IMU-856; the timing of initiation of Immunic's planned clinical trials; expectations regarding potential market size; the timing of the availability of data from Immunic's clinical trials; the timing of any planned investigational new drug application or new drug application; Immunic's plans to research, develop and commercialize its current and future product candidates; Immunic's ability to successfully collaborate with existing collaborators or enter into new collaboration agreements, and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of Immunic's product candidates; Immunic's commercialization, marketing and manufacturing capabilities and strategy; Immunic's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Immunic's competitors and industry; the impact of government laws and regulations; Immunic's ability to protect its intellectual property position; Immunic's listing on The Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of the company; the executive and board structure of the company; Immunic's estimates regarding future revenue, expenses, capital requirements and need for additional financing; the nature, strategy and focus of the company; and the other risks set forth in the company's filings with the Securities and Exchange Commission ("SEC").

Forward-looking statements included in this presentation are based on information available to Immunic as of the date of this presentation. Immunic does not undertake any obligation to update such forward- looking statements except as required by applicable law.

Summary and Highlights

Advanced and well-balanced pipeline:
Three products in development

Shares outstanding: 12.8 million
(as of May 1, 2020)

Phase 2 data read-outs ahead:
Several clinical phase 2 trials with IMU-838 expected to read-out in the next couple of months

Cash position of USD 18.6 million
(as of March 31, 2020)
USD 40 million ATM in place

Phase 2 trial in COVID-19 ongoing
IMU-838 is a potential COVID-19 solution
Broad-spectrum antiviral activity

Raised approximately USD 42 million in April and June 2020, substantially extending cash runway beyond important value inflection points

Development Pipeline

Program	Indication	Target	Preclinical	Phase 1	Phase 2	Phase 3
IMU-838	Multiple Sclerosis	DHODH				
	Ulcerative Colitis	DHODH				
	Crohn's Disease	DHODH				
	PSC	DHODH				Investigator-Sponsored Trial performed at Mayo Clinic / NIH
	COVID-19	DHODH				
IMU-935	Psoriasis	RORγt				
	Orphan AI Diseases	RORγt				
IMU-856	GI	Intestinal Barrier Function				

■ Completed or ongoing ■ In preparation or planned

Immunic THERAPEUTICS

IMU-838: Triple Attack on COVID-19

IMU-838 is an advanced clinical drug candidate with attractive pharmacokinetic, safety and tolerability profile with more than **650 individuals exposed to date**



IMU-838 attacks COVID-19 disease by three complementary mechanisms:

1. Inhibition of **virus replication** by depletion of nucleotide pool
2. Insufficient first immune response due to SARS-CoV-2 encoded interferon antagonists
   Induction of **innate immune response** by DHODH inhibition independent of interferon signaling
3. Excessive activation of adaptive immune response – “cytokine storm”
   Inhibition of “overreacting”, **cytokine high** producing immune cells

Immunic THERAPEUTICS

Immunic, Inc.
1200 Avenue of the Americas
New York City, NY 10036
USA

Immunic AG
IZB Martinsried
R&D Center
Munich, Germany

Immunic Research
GmbH
Weinberg Campus
Halle, Germany

Immunic Australia Pty. Ltd.
Melbourne, Australia

Daniel Vitt, Ph.D.

CEO and President

Phone: +49 89 2080 477 01

Email: ir@imux.com

Immunic THERAPEUTICS